Objectives for Today's Biologics Stakeholder Forum


Edward Chess, Ph.D. USP Biologics Stakeholder Forum Planning Committee Chair



Biologics Stakeholder Forum (SF) charter

The goals of the Biologics Stakeholder Forum are:


- To learn the needs of biologics stakeholders that may intersect with USP's core capabilities.
- 2. To share new information with the stakeholders and obtain feedback.
- 3. To recruit volunteers to support USP's Council of Experts.
- 4. To identify subject matter experts who can provide guidance or resources to support the execution of USP's biologics strategy.



2022 Biologics SF planning committee



- Ed Chess, Chair, Consultant, USA
- Linda Narhi, Consultant, USA
- Ben Clarke, USP
- Gael Debauve, UCB, Belgium
- Lauren Drouin, LogicBio Therapeutics, USA
- Marcus Haindl, Roche Diagnostics, Germany
- Maura Kibbey, USP
- Kik-Seong (KS) Lim, Metagenomi, USA
- Jacqueline D. Starkes, USP
- Nathan Weinstock, Biogen, USA



First Biologics SF, Jan 10, 2020



Multi Attribute Methods for Biologics Topics & Speakers

- Development and Application of a Multi-Attribute Method (MAM)
 - Jette Wypych, Ph.D., Amgen
- Enhancing Biotherapeutic Process and Product Knowledge with the Multi-Attribute Method (MAM)
 - Andrew Dawdy, Ph.D., Pfizer
- Quality Considerations for the Multi-Attribute method (MAM)
 - Sarah Rogstad, Ph.D., FDA
- USP Standard to Support Multi-Attribute Methods (MAM) and Mass Spectrometry,
 - Diane McCarthy, Ph.D., USP

First Biologics SF, Jan 10, 2020



Discussion and Outcomes

- Recommendations from breakout sessions
 - There is a need for best practices for MAM and attendees supported developing a general chapter on best practices for MAM
 - Physical standards will be useful, with particular interest in matched sets of intact and predigested mAbs
- Outcome
 - MAM Expert Panel has drafted a general chapter on best practices (targeting PF49(4))
 - Digested USP mAb001, 002, 003 standards in development with external partner
- Other MAM activities
 - Collaborations to assess MAM focus on sample preparation and tech transfer
 - USP MAM Exchange Online Community join at mam.usp.org

Second Biologics SF, Aug 10 & 12, 2021



Innovative Analytical and Digital Solutions to Advance Biomanufacturing and Product Quality *Topics & Speakers*

Day 1 Analytical Day

- CHO Cell Process Monitoring of Quality Attributes using Raman Spectroscopy at Manufacturing Scale
 - Caitlin O'Mahony Hartnett, Ph.D., Scientist, Janssen Sciences Ireland
- In-line Viral Inactivation: Monitoring Key Process Parameters to Ensure Effectiveness
 - Michael Phillips, Ph.D., Director-Bioprocess Development, MilliporeSigma
- Enabling Real Time Release Testing (RTRT) with Multi-Attribute Methods
 - Galahad Deperalta, Ph.D., Senior Scientist and Innovation Group Leader, Analytical Development and Quality Control, Genentech

Second Biologics SF, Aug 10 & 12, 2021



Innovative Analytical and Digital Solutions to Advance Biomanufacturing and Product Quality *Topics & Speakers*

Day 2 Digital Day

• How can in silico Models be Accepted in lieu of Lab Experiments and Manufacturing Runs?

- Marcus Fiadeiro, Associate Director, Purification Development, Sanofi
- Siddhartha Jain, Ph.D., Director, MSAT Digital, Sanofi
- The Potential of Hybrid Process Modeling and Digital Twins to Master the Goals of Industry 4.0 in Bioprocessing
 - Michael Sokolov, Ph.D., COO and Co-Founder of DataHow AG
- Advanced Technology for Manufacturing Process Control
 - Riley Myers, Ph.D., Emerging Technology Team/OPQ and Lead Biologist, Office of Biotechnology Products, CDER, US FDA

Second Biologics SF, Aug 10 & 12, 2021



Discussion and Outcomes

- Recommendations from breakout sessions
 - USP to focus on analytical solutions as digital solutions are not yet mature enough for standardization
 - Host a roundtable on PAT for biomanufacturing
- Outcome
 - USP Roundtable on Implementation of At-Line and In-Line Analytical Tools for Biomanufacturing Process Development and Monitoring held Feb 24, 2022
 - USP to compile the ideas shared by the experts into a technical article outlining challenges and proposals to address those challenges
 - Creation of In-line/At-line Monitoring and Real-time Release Testing Expert Panel to draft a chapter on best practices
 - Call for Candidates for Expert Panel membership open now!

USP Biologics Stakeholder Forum Webinar

NOTICE TO PARTICIPANTS:

- During the main meeting, virtual attendees were muted. Please ask questions or make comments at any time by using the Q&A feature.
- Questions will be collated for the Q&A/Panel discussion after all the speakers have presented.
- Questions may be initially posed for one speaker, but other speakers are also free to join in and provide answers
- Today's event will be recorded strictly for notetaking purposes and destroyed afterward.
- You will receive a satisfaction survey after today's event. Please send us your input!

Questions VIA the Q&A Feature:

- Open the Q&A function by clicking on the 3 dots at the bottom of the screen and then clicking on Q&A.
- All questions/comments should be sent to "everyone."

Questions during the afternoon moderated session:

Attendees in person should use the microphones near them to ask or respond to questions from the moderator. Virtual attendees can submit questions via the Q&A feature, and a USP staff member will read your question to the moderator when possible.

Third Biologics SF, Oct 26, 2022



Collaborating to Solve CMC Challenges and Support Efficient Development of Lentiviral-Mediated CAR T Cell Therapies

- 8:45 a.m. 9:15 a.m. **Registration and Information** Meeting Center Foyer
- 9:15 a.m. 9:30 a.m. USP Welcome and Opening Remarks Speaker: Maura Kibbey, Ph.D., Director, Biologics Marketing, USP
- 9:30 a.m. 9:40 a.m. Introduction and Objectives for today's Biologics Stakeholder Forum Moderator: Edward Chess, Ph.D., USP Biologics Stakeholder Forum Planning Committee, Chair

9:40 a.m. – 10:05 a.m. USP standards to support the development of cell and gene therapy products Speaker: Ben Clarke, Ph.D., Senior Scientist II, Global Biologics, USP

10:05 a.m. - 10:30 a.m.Regulatory Considerations for the Development of Potency Assays during CAR T Cell DevelopmentSpeaker: Andrew Timmons, Ph.D., Biologist, U.S. Food and Drug Administration (FDA)

Third Biologics SF, Oct 26, 2022



Collaborating to Solve CMC Challenges and Support Efficient Development of Lentiviral-Mediated CAR T Cell Therapies

- 10:30 a.m. 10:55 a.m.Approaches to Potency Testing for Chimeric Antigen Receptor T CellsSpeaker: Shree Joshi, Senior Scientist, BioTD, Analytical Development, Janssen Pharmaceutical
- 10:55 a.m. 11:10 a.m. Morning Break
- 11:10 a.m. 11:35 a.m.
 Implementation of QbD principles in potency assay development and overcoming challenges on the road to commercialization
 Speaker: Kim Nguyen, Ph.D., Head of Product Attribute Sciences, Kite Pharma

11:35 a.m. – 12:00 p.m.Q&A Panel DiscussionModerator: Edward Chess, Ph.D., USP Biologics Stakeholder Forum Planning Committee, Chair
Panelists: Fouad Atouf, Ben Clarke, Andrew Timmons, and Shree Joshi

12:00 p.m. – 1:00 p.m. Lunch and networking break for in-person attendees

Third Biologics SF, Oct 26, 2022



Collaborating to Solve CMC Challenges and Support Efficient Development of Lentiviral-Mediated CAR T Cell Therapies

1:00 p.m. – 4:30 p.m.	 Moderated Discussion Moderator: Kok-Seong (KS) Lim, Ph.D., Senior Director of Analytical Sciences, Metagenomi Biological activity and potency Safety (replication-competent virus, integration, etc.)
2:30 p.m. – 2:45 p.m.	Afternoon Break
4:30 p.m. – 5:00 p.m.	Next steps and closing remarks Speaker: Linda Narhi, Ph.D., USP Biologics Stakeholder Forum Planning Committee, Vice-Chair

Your moderators

- Ed Chess, Ph.D., Consultant
- Linda Narhi, Ph.D., Consultant
- KS Lim, Ph.D., Metagenomi



Thank You



Empowering a healthy tomorrow